查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1542911

全球即時診斷市場 - 2024-2031

Global Point-of-Care Diagnostics Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

即時診斷市場規模

2023年，全球床邊診斷市場規模達497.3億美元，預計2031年將達到1,157.5億美元，2024-2031年預測期間複合年成長率為11.5%。

POC 診斷測試可快速提供結果，從而改善患者護理。即時診斷的應用包括診斷和檢測血糖值、傳染病、心臟檢查等。這些設備用於醫院、診所和患者家中，以快速回應各種醫療測試。

即時診斷市場研究分析提供了包含定量和定性資料的市場深入展望。它根據市場細分對全球市場進行了展望和預測。它還提供了全球即時診斷市場規模和成長，以及到 2029 年全球市場（包括美國、加拿大、巴西、德國、義大利等主要國家）的最新趨勢、機會和預測。 、阿拉伯聯合大公國、沙烏地阿拉伯、南非、日本、中國、印度、韓國、澳洲以及全球其他國家。

在所有地區中，北美地區預計將在預測期內佔據全球市場的最大佔有率。美國和加拿大的即時診斷市場佔有最大佔有率。而歐洲即時診斷市場預計將在 2023 年至 2030 年期間繼續在全球佔有一席之地。

即時診斷市場動態

最新技術的採用熱潮和認知度的不斷提高預計將推動市場成長。

不斷成長的技術進步是促進市場成長的關鍵因素之一，此外，具有多重功能的POC 考試的成長、透過會議和活動增加關注度、醫療保健分散化以及不斷成長的市場將為課程的現場護理診斷創造新的可能性在預測期內。

照護端診斷設備的召回預計將阻礙市場成長。

2021 年 10 月，美國食品藥物管理局 (FDA) 警告稱，某些批次的 Ellume COVID-19 家庭測試因製造缺陷而出現假陽性結果。該公司自願召回指定數量的Covid-19 抗原測試，該測試於2020 年12 月獲得緊急使用授權(EUA)。 Ellume 已召回近20 萬個測試套件，約佔Ellume 已出貨350 萬個測試套件的5.6%美國約有 427,000 個檢測試劑盒受到此問題的影響。因此，綜合上述因素，預計市場在預測期內將受到阻礙。

產業分析

即時診斷市場根據各種行業因素（例如波特五力、法規核准、供應鏈分析、定價分析等）提供了對市場的深入分析。

COVID-19 對全球即時診斷市場的影響：

COVID-19 大流行對醫療保健系統和市場產生了積極影響。阻止 SARS-CoV-2 傳播和有效管理 COVID-19 感染的最有效公共衛生措施之一是及早發現和隔離受影響人群。 SARS-CoV-2感染的診斷是基於臨床症狀，並透過使用逆轉錄聚合酶鏈反應在呼吸道樣本中尋找病毒RNA（RT-PCR）進行驗證。標準 RT-PCR 程序耗時、昂貴且技術上具有挑戰性，因此在資源有限的情況下，它們不適合進行現場護理和大規模篩檢。在最近開發的即時護理 (POC)、抗原和血清學檢測以及監測操作中擴展 COVID-19 檢測試劑盒是經濟實惠的。此外，全球診斷聯盟創新新診斷基金會（FIND）於2021年4月宣布將向Biomeme、Bioneer、Qlife和SD Biosensor投資2,100萬美元，以加速開發、生產和推出具有成本效益的點護理分子診斷平台，可以識別多種致病病原體，包括COVID-19。因此，綜合以上因素，預測期內市場可望提振。

即時診斷市場區隔分析

側流分析領域預計將在即時診斷市場中佔據最大的市場佔有率

到 2021 年，側向層析檢測領域將佔據最大的市場佔有率。側向層析測試也很簡單，無需特殊設備、技能或經驗。傳統的側向層析測試產生定性或半定量結果，而定量檢測需要專業設備。例如，位於加拿大安大略省伯靈頓的生物技術公司 Cytodiagnostics 提供人類 IgG Fc 側流檢測試劑盒，該試劑盒可在 20 分鐘內檢測細胞培養基和純化蛋白質樣本中的人類 IgG Fc。其常見應用包括監測重組抗體的表達量和在純化過程中追蹤人類 Fc 標籤蛋白。

此外，該公司越來越注重開發基於側流檢測的創新床邊 (POC) 設備。例如，雅培實驗室（美國）於 2019 年推出了 ARCHITECT STAT 肌鈣蛋白 I 血液檢測，而西門子公司則推出了用於臨床診斷的 CLINITEK 微量白蛋白 2 試紙條。因此，從上述因素來看，該細分市場在預測期內佔據了最大的市場佔有率。

即時診斷市場地理佔有率

北美地區在全球即時診斷市場中佔有最大的市場佔有率

2021 年，北美佔據了最大的市場佔有率。預測期內提振市場的一些因素。例如，根據國際糖尿病聯盟(IDF) 的數據，到2021 年，北美和加勒比地區將有4,800 萬成年人患有糖尿病，年齡從20 歲到79 歲不等。 % 左右括號。此外，糖尿病造成的醫療費用至少為 9,660 億美元，佔成人總支出的 9%。因此，增加了對血糖監測產品的需求。 PoC 測試廣泛用於測量住院患者的血糖水平，並根據血糖變化快速決定治療方案。 POC血糖檢測要準確，必須考慮檢測前、檢測中和檢測後的各種參數。

此外，醫療科技公司 Bond Digital Health 於 2022 年 5 月 18 日啟動眾籌活動，完成一輪 150 萬歐盟投資。該企業堅信，數位化 PoC 診斷有潛力徹底改變醫療保健並提高全球範圍內的可及性。因此，從上述因素來看，北美地區預計將在預測期內佔據最大的市場佔有率。

即時診斷市場公司

床邊診斷市場的主要參與者包括 F. Hoffmann La-Roche Ltd.、Abbott、Siemens Healthcare GmbH、Quidel Corporation、Cepheid、BD、Thermo Fisher Scientific、Biomerieux、Chembio Diagnostics, Inc.、EKF Diagnostics。

F.霍夫曼拉羅氏有限公司：

概述 ：

Hoffmann-La Roche Ltd 是專注於研究的醫療保健領域的主要市場領導者之一，擁有製藥和診斷領域的綜合產品組合。它是最大的生物技術公司之一，在免疫學、傳染病、腫瘤學、眼科和神經科學領域擁有真正的差異化藥物。它是體外和基於組織的癌症診斷的全球領導者，也是糖尿病管理領域的領導者。其個人化醫療保健策略旨在提供藥物和診斷，以實際改善患者的健康、生活品質和存活率。此外，羅氏分子是羅氏診斷解決方案以客戶為中心的四個領域之一，開發、製造和供應各種創新分子診斷產品、測試、平台和技術，用於識別和量化來自不同生物體的DNA 和RNA。

產品組合：

cobas h 232 POC系統：cobas h 232 POC系統是一款攜帶式POC系統，可支援對有胸痛和呼吸困難症狀的患者進行最佳化治療，因為它可以根據客觀結果提供對患者病情的現場診斷和評估。

全球照護端診斷市場報告將提供大約的資訊。 45+市場資料表，40+圖表，180頁

目錄

第 1 章：方法與範圍

第 2 章：市場定義與概述

第 3 章：執行摘要

第 4 章：市場動態

  • 市場影響因素
    • 促進要素
      • 照護端設備開發的技術進步預計將推動市場成長。
    • 限制：
      • 照護端診斷設備的召回預計將阻礙市場成長。
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特的五力
  • 監管分析
  • 供應鏈分析
  • 定價分析

第 6 章：COVID-19 分析

第 7 章：按產品類型

  • 血糖監測產品
    • 條帶
    • 米
    • 刺血針和採血裝置
    • 其他
  • 心臟代謝監測產品
    • 心臟標記測試產品
    • 血液氣體/電解質測試產品
    • HBA1C 測試產品
    • 其他
  • 傳染病檢測產品
    • COVID-19 測試產品
    • 流感檢測產品
    • HIV檢測產品
    • 丙型肝炎檢測產品
    • 艱難梭菌產品
    • 乙肝病毒檢測產品
    • 肺炎或鏈球菌相關感染
    • 呼吸道合胞病毒 (RSV) POC
    • 其他
  • 凝血監測產品
    • PT/INR 測試產品
    • 活化凝血時間 (ACT/APTT) 測試產品
    • 其他
  • 懷孕和生育測試產品
    • 驗孕產品
    • 生育力檢測產品
    • 其他
  • 腫瘤/癌症標記檢測產品
  • 濫用藥物測試產品
  • 糞便隱匿性測試產品
  • 其他

第 8 章：按平台

  • 側流分析
  • 免疫測定
  • 微流控
  • 量油尺
  • 分子診斷
  • 其他

第 9 章：按購買方式

  • OTC測試產品
  • 基於處方的測試產品

第 10 章：最終用戶

  • 醫院
  • 門診手術中心
  • 診斷中心
  • 居家護理
  • 臨床實驗室
  • 其他

第 11 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太地區其他地區
  • 中東和非洲

第 12 章：競爭格局

  • 主要進展和策略
  • 公司股份分析
  • 產品基準化分析
  • 值得關注的重點公司名單

第 13 章：公司簡介

  • F. Hoffmann La-Roche Ltd.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務概覽
  • Abbott
  • Siemens Healthcare GmbH
  • Quidel Corporation
  • Cepheid
  • BD
  • Thermo Fisher Scientific
  • Biomerieux
  • Chembio Diagnostics, Inc.
  • EKF diagnostics (*LIST NOT EXHAUSTIVE)

第 14 章：數據M

簡介目錄
Product Code: CD1063

Point-of-Care Diagnostics Market Size

The Global Point-of-Care Diagnostics Market reached US$ 49.73 billion in 2023 and is expected to reach US$ 115.75 billion by 2031, growing at a CAGR of 11.5% during the forecast period 2024-2031.

POC diagnostic tests provide speedy findings, which improves patient care. Applications of point-of-care diagnostics include diagnosing and detecting glucose levels, infectious diseases, cardiac tests, and among others. These devices are utilized in hospitals, clinics, and patient's homes to respond quickly to various medical tests.

Point-of-Care diagnostics market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Point-of-Care diagnostics market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. The Point-of-Care diagnostics market in the United States and Canada produces the utmost share. Whereas the European Point-of-Care diagnostics market is projected to continue its presence globally during the period of 2023-2030.

Point-of-Care Diagnostics Market Dynamics

The boom in the adoption of the latest technology and growing cognizance are expected to drive market growth.

Rising technological advancements is one of the critical component enhancing the marketplace rise, additionally growing POC exams with multiplexing abilities, increasing focus through conferences and events, healthcare decentralization, and rising markets will create new possibilities for the point-of-care diagnostics for the course during the forecasting period.

Recall of Point of Care diagnostic devices is expected to hamper the market growth.

In October 2021, The US Food and Drug Administration (FDA) warned that certain batches of the Ellume COVID-19 Home Test provided false positive findings due to a manufacturing fault. The company voluntarily recalled specified quantities of its Covid-19 antigen test, which received Emergency Use Authorization (EUA) in December 2020. Nearly 200,000 test kits Ellume has been subject to recall make up approximately 5.6% of the 3.5 million test kits Ellume has shipped to the US, with about 427,000 test kits affected by the problem overall. Thus, from the above factors, the market is expected to be hampered in the forecast period.

Industry Analysis

The point-of-care diagnostics market provides an in-depth analysis of the market based on various industry factors such as porter five forces, regulatory approvals, supply chain analysis, pricing analysis etc.

COVID-19 Impact on the global Point-of-Care Diagnostics Market:

The COVID-19 pandemic has positively impacted healthcare systems and the market. One of the most effective public health measures to stop the spread of SARS-CoV-2 and to effectively manage COVID-19 infections is early detection and isolation of affected people. The diagnosis of SARS-CoV-2 infection is based on clinical symptoms and verified by employing reverse transcription polymerase chain reaction to find the viral RNA in respiratory samples (RT-PCR). Standard RT-PCR procedures are time-consuming, expensive, and technically challenging, making them a poor choice for point-of-care and mass screening in situations with limited resources. It is affordable to scale COVID-19 testing kits at the point-of-care (POC), antigen, and serological tests that have recently been developed, as well as for surveillance operations. Moreover, the global diagnostics alliance Foundation for Innovative New Diagnostics (FIND) announced in April 2021 that it would invest USD 21 million in Biomeme, Bioneer, Qlife, and SD Biosensor to speed up the development, production, and introduction of cost-effective point-of-care molecular diagnostic platforms that can identify multiple disease-causing pathogens, including COVID-19. Thus, from the above factors, the market is expected to boost in the forecast period.

Point-of-Care Diagnostics Market Segment Analysis

Lateral Flow Assays segment is expected to hold the largest market share in point-of-care diagnostics market

The lateral flow assays segment is accounted for the largest market share in 2021. The segment benefits because these are widely used due to their low cost, ease of use, and speed. Lateral flow tests are also simple without special equipment, skills, or experience. Traditional lateral flow tests produce qualitative or semi-quantitative results, whereas quantitative detection requires specialist equipment. For instance, Cytodiagnostics, a biotechnology company based in Burlington, Ontario, Canada, provides the Human IgG Fc Lateral Flow Assay Kit, a 20-minute assay to detect Human IgG Fc in cell culture media and purified protein samples. Its common applications include monitoring expression levels of recombinant antibodies and tracking human Fc-tagged proteins during purification.

Moreover, companies are increasingly focusing on developing innovative lateral flow assay-based point-of-care (POC) devices. For instance, Abbott Laboratories (US) introduced the ARCHITECT STAT Troponin I Blood Test in 2019, while Siemens AG introduced the CLINITEK Microalbumin 2 strips for clinical diagnostics. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Point-of-Care Diagnostics Market Geographical Share

North America region holds the largest market share in the global point-of-care diagnostics market

North America accounted for the largest market share in 2021. The increasing prevalence of diabetes, technological advancement in the point of care devices, the rising presence of corroborating government bodies that elevate point-of-care diagnostics or testing in the region and the launch of the product by the key market players in the region are some of the factors the market is expected to boost in the forecast period. For instance, according to the International Diabetes Federation (IDF), the North America and Caribbean region will have 48 million adults with diabetes in 2021, ranging in age from 20 to 79. This amounts to roughly 13% of the local population in this age bracket. Besides, diabetes contributed to at least USD 966 billion in medical costs, or 9% of all adult spending. Therefore, it has increased the demand for glucose monitoring products. PoC testing is widely used to measure glucose levels in hospitalized patients and quickly decide on a course of therapy in response to changes in blood sugar. POC glucose testing is to be accurate, various parameters must be considered before, during, and after the tests.

Moreover, Bond Digital Health, a MedTech company, started a crowdfunding campaign on May 18, 2022, to finish an EU 1.5 million investment round. The business is convinced that digitized PoC diagnostics have the potential to revolutionize healthcare and increase accessibility on a global scale. Thus, from the above factors, the North America region is expected to hold the largest market share in the forecast period.

Point-of-Care Diagnostics Market Companies

Major key players in the point-of-care diagnostics market are F. Hoffmann La-Roche Ltd., Abbott, Siemens Healthcare GmbH, Quidel Corporation, Cepheid, BD, Thermo Fisher Scientific, Biomerieux, Chembio Diagnostics, Inc., EKF diagnostics.

F. Hoffmann La-Roche Ltd:

Overview:

Hoffmann-La Roche Ltd is one of the key market leaders in research-focused healthcare with combined portfolio in pharmaceuticals and diagnostics. It is one of the largest biotech companies, with truly differentiated medicines in immunology, infectious diseases, oncology, ophthalmology, and neuroscience. It is a global leader in in-vitro and tissue-based cancer diagnostics and a frontrunner in diabetes management. Its personalized healthcare strategy aims to provide medicines and diagnostics that enable tangible improvements in patients' health, quality of life and survival. Moreover, Roche Molecular, is one of four customer-focused areas of Roche Diagnostics Solutions, develops, manufactures and supplies a wide array of innovative molecular diagnostic products, tests, platforms and technologies used to identify and quantify DNA and RNA from different organisms.

Product Portfolio:

cobas h 232 POC system: cobas h 232 POC system is a portable POC system that supports the optimized treatment of patients with symptoms of chest pain and dyspnea because it provides on-the-spot diagnosis and assessment of the patient's condition based on objective results.

The global point-of-care diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancements in the Point of Care device development are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Recall of Point of Care diagnostic devices is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Glucose Monitoring Products*
    • 7.2.1. Strips
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.2. Meters
    • 7.2.3. Lancets & Lancing Devices
    • 7.2.4. Others
  • 7.3. Cardiometabolic Monitoring Products
    • 7.3.1. Cardiac Marker Testing Products
    • 7.3.2. Blood Gas/Electrolytes Testing Products
    • 7.3.3. HBA1C Testing Products
    • 7.3.4. Others
  • 7.4. Infectious Disease Testing Products
    • 7.4.1. COVID-19 Testing Products
    • 7.4.2. Influenza Testing Products
    • 7.4.3. HIV Testing Products
    • 7.4.4. Hepatitis C Testing Products
    • 7.4.5. Clostridium Difficile products
    • 7.4.6. HBV testing products
    • 7.4.7. Pneumonia or Streptococcus Associated Infections
    • 7.4.8. Respiratory Syncytial Virus (RSV) POC
    • 7.4.9. Others
  • 7.5. Coagulation Monitoring Products
    • 7.5.1. PT/INR Testing Products
    • 7.5.2. Activated Clotting Time (ACT/APTT) Testing Products
    • 7.5.3. Others
  • 7.6. Pregnancy & Fertility Testing Products
    • 7.6.1. Pregnancy testing products
    • 7.6.2. Fertility testing products
    • 7.6.3. Others
  • 7.7. Tumor/Cancer Marker Testing Products
  • 7.8. Drugs-of-Abuse Testing Products
  • 7.9. Fecal Occult Testing Products
  • 7.10. Others

8. By Platform

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Platform
    • 8.1.2. Market Attractiveness Index, By Platform Segment
  • 8.2. Lateral Flow Assays*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Immunoassays
  • 8.4. Microfluidics
  • 8.5. Dipsticks
  • 8.6. Molecular Diagnostics
  • 8.7. Others

9. By Mode of Purchase

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Purchase
    • 9.1.2. Market Attractiveness Index, By Mode of Purchase Segment
  • 9.2. OTC Testing Products*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Prescription-Based Testing Products

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Ambulatory Surgical Centers
  • 10.4. Diagnostic Centers
  • 10.5. Home Care
  • 10.6. Clinical Laboratories
  • 10.7. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Platform
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Purchase
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Platform
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Purchase
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Platform
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Purchase
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Platform
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Purchase
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Platform
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Purchase
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. F. Hoffmann La-Roche Ltd.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Abbott
  • 13.3. Siemens Healthcare GmbH
  • 13.4. Quidel Corporation
  • 13.5. Cepheid
  • 13.6. BD
  • 13.7. Thermo Fisher Scientific
  • 13.8. Biomerieux
  • 13.9. Chembio Diagnostics, Inc.
  • 13.10. EKF diagnostics (*LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us